Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

QoSRP: A Cross-layer QoS Channel-Aware Routing Protocol for the Internet of Underwater Acoustic Sensor Networks.

Faheem M, Butt RA, Raza B, Alquhayz H, Ashraf MW, Shah SB, Ngadi MA, Gungor VC.

Sensors (Basel). 2019 Nov 2;19(21). pii: E4762. doi: 10.3390/s19214762.

2.

Lack of Detection of the Analgesic Properties of PF-05089771, a Selective Nav 1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects.

Siebenga P, van Amerongen G, Hay JL, McDonnell A, Gorman D, Butt R, Groeneveld GJ.

Clin Transl Sci. 2019 Oct 23. doi: 10.1111/cts.12712. [Epub ahead of print]

PMID:
31642607
3.

Crohn's disease with progressive renal impairment.

Seidelin JB, Riis LB, Butt RA.

Gastroenterology. 2019 Sep 26. pii: S0016-5085(19)41346-2. doi: 10.1053/j.gastro.2019.09.012. [Epub ahead of print] No abstract available.

PMID:
31563621
4.

Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.

van Amerongen G, Siebenga PS, Gurrell R, Dua P, Whitlock M, Gorman D, Okkerse P, Hay JL, Butt RP, Groeneveld GJ.

Br J Anaesth. 2019 Aug;123(2):e194-e203. doi: 10.1016/j.bja.2018.12.006. Epub 2019 Jan 31.

5.

Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.

Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds DS, DiVentura B, Abou-Khalil B, Gelfand M, Pollard J, Hogan RE, Krauss G, Sperling M, Vazquez B, Wechsler RT, Friedman D, Butt RP, French J.

Neurology. 2019 Apr 9;92(15):e1786-e1795. doi: 10.1212/WNL.0000000000007271. Epub 2019 Mar 15.

PMID:
30877186
6.

Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs.

Siebenga PS, van Amerongen G, Okkerse P, Denney WS, Dua P, Butt RP, Hay JL, Groeneveld GJ.

Eur J Pain. 2019 Jul;23(6):1129-1140. doi: 10.1002/ejp.1379. Epub 2019 Apr 5.

7.

Gut Microbiota and Energy Homeostasis in Fish.

Butt RL, Volkoff H.

Front Endocrinol (Lausanne). 2019 Jan 24;10:9. doi: 10.3389/fendo.2019.00009. eCollection 2019. Review.

8.

A Retrospective Analysis on the Cystic Echinococcosis Cases Occured in Northeastern Punjab Province, Pakistan.

Khan A, Zahoor S, Ahmed H, Malik U, Butt RA, Muzam MS, Kilinc SG, Noor N, Zahoor S, Afzal MS, Mansur H, Irum S, Simsek S.

Korean J Parasitol. 2018 Aug;56(4):385-390. doi: 10.3347/kjp.2018.56.4.385. Epub 2018 Aug 31.

9.

A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain.

Gurrell R, Dua P, Feng G, Sudworth M, Whitlock M, Reynolds DS, Butt RP.

Pain. 2018 Sep;159(9):1742-1751. doi: 10.1097/j.pain.0000000000001267.

PMID:
29787472
10.

Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy.

McDonnell A, Collins S, Ali Z, Iavarone L, Surujbally R, Kirby S, Butt RP.

Pain. 2018 Aug;159(8):1465-1476. doi: 10.1097/j.pain.0000000000001227.

PMID:
29578944
11.

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Nickolls SA, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown AR, Stead C, Mead A, Watson C, Hsu C, Owen RM, Pike A, Fish RL, Chen L, Qiu R, Morris ED, Feng G, Whitlock M, Gorman D, van Gerven J, Reynolds DS, Dua P, Butt RP.

Br J Pharmacol. 2018 Feb;175(4):708-725. doi: 10.1111/bph.14119. Epub 2018 Jan 18. Erratum in: Br J Pharmacol. 2019 Jan;176(1):127.

12.

Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models.

Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, Hay JL, Groeneveld GJ, Butt RP.

Br J Clin Pharmacol. 2018 Feb;84(2):301-309. doi: 10.1111/bcp.13448. Epub 2017 Nov 28.

13.

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

Swain NA, Batchelor D, Beaudoin S, Bechle BM, Bradley PA, Brown AD, Brown B, Butcher KJ, Butt RP, Chapman ML, Denton S, Ellis D, Galan SRG, Gaulier SM, Greener BS, de Groot MJ, Glossop MS, Gurrell IK, Hannam J, Johnson MS, Lin Z, Markworth CJ, Marron BE, Millan DS, Nakagawa S, Pike A, Printzenhoff D, Rawson DJ, Ransley SJ, Reister SM, Sasaki K, Storer RI, Stupple PA, West CW.

J Med Chem. 2017 Aug 24;60(16):7029-7042. doi: 10.1021/acs.jmedchem.7b00598. Epub 2017 Aug 10.

PMID:
28682065
14.

The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study.

Okkerse P, van Amerongen G, de Kam ML, Stevens J, Butt RP, Gurrell R, Dahan A, van Gerven JM, Hay JL, Groeneveld GJ.

Br J Clin Pharmacol. 2017 May;83(5):976-990. doi: 10.1111/bcp.13183. Epub 2017 Jan 9.

15.

Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia.

Cao L, McDonnell A, Nitzsche A, Alexandrou A, Saintot PP, Loucif AJ, Brown AR, Young G, Mis M, Randall A, Waxman SG, Stanley P, Kirby S, Tarabar S, Gutteridge A, Butt R, McKernan RM, Whiting P, Ali Z, Bilsland J, Stevens EB.

Sci Transl Med. 2016 Apr 20;8(335):335ra56. doi: 10.1126/scitranslmed.aad7653.

PMID:
27099175
16.

Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release.

Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, Wilbrey A, Payne EC, Gutteridge A, Cox PJ, Doyle R, Printzenhoff D, Lin Z, Marron BE, West C, Swain NA, Storer RI, Stupple PA, Castle NA, Hounshell JA, Rivara M, Randall A, Dib-Hajj SD, Krafte D, Waxman SG, Patel MK, Butt RP, Stevens EB.

PLoS One. 2016 Apr 6;11(4):e0152405. doi: 10.1371/journal.pone.0152405. eCollection 2016.

17.

Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.

Jones HM, Butt RP, Webster RW, Gurrell I, Dzygiel P, Flanagan N, Fraier D, Hay T, Iavarone LE, Luckwell J, Pearce H, Phipps A, Segelbacher J, Speed B, Beaumont K.

Clin Pharmacokinet. 2016 Jul;55(7):875-887. doi: 10.1007/s40262-015-0365-0.

PMID:
26895021
18.

Crystal structure of 4-{[(2,4-di-hydroxy-benzyl-idene)amino]-meth-yl}cyclo-hexane-carb-oxy-lic acid.

Danish M, Akbar S, Tahir MN, Butt RA, Ashfaq M.

Acta Crystallogr E Crystallogr Commun. 2015 Nov 28;71(Pt 12):o995-6. doi: 10.1107/S2056989015022343. eCollection 2015 Dec 1.

19.

Benign and Malignant Male Breast Diseases: Radiologic and Pathologic Correlation.

Yen PP, Sinha N, Barnes PJ, Butt R, Iles S.

Can Assoc Radiol J. 2015 Aug;66(3):198-207. doi: 10.1016/j.carj.2015.01.002. Epub 2015 Jun 12. Review.

20.

Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis.

Shields SD, Butt RP, Dib-Hajj SD, Waxman SG.

PLoS One. 2015 Mar 6;10(3):e0119067. doi: 10.1371/journal.pone.0119067. eCollection 2015.

21.

A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability.

Payne CE, Brown AR, Theile JW, Loucif AJ, Alexandrou AJ, Fuller MD, Mahoney JH, Antonio BM, Gerlach AC, Printzenhoff DM, Prime RL, Stockbridge G, Kirkup AJ, Bannon AW, England S, Chapman ML, Bagal S, Roeloffs R, Anand U, Anand P, Bungay PJ, Kemp M, Butt RP, Stevens EB.

Br J Pharmacol. 2015 May;172(10):2654-70. doi: 10.1111/bph.13092. Epub 2015 Apr 10.

22.

Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.

Di Valentin T, Biagi J, Bourque S, Butt R, Champion P, Chaput V, Colwell B, Cripps C, Dorreen M, Edwards S, Falkson C, Frechette D, Gill S, Goel R, Grant D, Hammad N, Jeyakumar A, L'espérance M, Marginean C, Maroun J, Nantais M, Perrin N, Quinton C, Rother M, Samson B, Siddiqui J, Singh S, Snow S, St-Hilaire E, Tehfe M, Thirlwell M, Welch S, Williams L, Wright F, Goodwin R.

Curr Oncol. 2013 Oct;20(5):e455-64. doi: 10.3747/co.20.1638.

23.

Coomassie blue as a near-infrared fluorescent stain: a systematic comparison with Sypro Ruby for in-gel protein detection.

Butt RH, Coorssen JR.

Mol Cell Proteomics. 2013 Dec;12(12):3834-50. doi: 10.1074/mcp.M112.021881. Epub 2013 Sep 16.

24.

Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.

McCormack K, Santos S, Chapman ML, Krafte DS, Marron BE, West CW, Krambis MJ, Antonio BM, Zellmer SG, Printzenhoff D, Padilla KM, Lin Z, Wagoner PK, Swain NA, Stupple PA, de Groot M, Butt RP, Castle NA.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):E2724-32. doi: 10.1073/pnas.1220844110. Epub 2013 Jul 1.

25.

Polyostotic Paget's disease.

Butt ST, Fatima S, Butt R, Nasir W, Jameel G, Irfan J.

J Coll Physicians Surg Pak. 2012 Jul;22(7):461-3. doi: 07.2012/JCPSP.461463.

PMID:
22747870
26.

Alterations in protein and gene expression within the barrel cortices of ZnT3 knockout mice: experience-independent and dependent changes.

Nakashima AS, Butt RH, Dyck RH.

Neurochem Int. 2011 Nov;59(6):860-70. doi: 10.1016/j.neuint.2011.08.007. Epub 2011 Aug 19.

PMID:
21871936
27.

Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine.

Benson N, Snelder N, Ploeger B, Napier C, Sale H, Birdsall NJ, Butt RP, van der Graaf PH.

Br J Pharmacol. 2010 May;160(2):389-98. doi: 10.1111/j.1476-5381.2010.00719.x.

28.

Clipping of intracranial aneurysms--3 years study.

Ahmad M, Butt RM, Ahmad N.

J Ayub Med Coll Abbottabad. 2008 Jul-Sep;20(3):75-7.

PMID:
19610523
29.

Jugular foramen schwannoma--a very rare entity.

Ahmad M, Butt RM, Ahmad N.

J Ayub Med Coll Abbottabad. 2009 Apr-Jun;21(2):174-5.

PMID:
20524500
30.

Treatment of uncomplicated plasmodium falciparum malaria with quinine-doxycycline combination therapy.

Ejaz A, Haqnawaz K, Hussain Z, Butt R, Awan ZI, Bux H.

J Pak Med Assoc. 2007 Oct;57(10):502-5.

31.

Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.

Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA.

J Med Chem. 2007 Jul 26;50(15):3442-56. Epub 2007 Jun 26.

PMID:
17591762
32.

Enabling coupled quantitative genomics and proteomics analyses from rat spinal cord samples.

Butt RH, Pfeifer TA, Delaney A, Grigliatti TA, Tetzlaff WG, Coorssen JR.

Mol Cell Proteomics. 2007 Sep;6(9):1574-88. Epub 2007 May 17.

33.

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.

Fish PV, Barber CG, Brown DG, Butt R, Collis MG, Dickinson RP, Henry BT, Horne VA, Huggins JP, King E, O'Gara M, McCleverty D, McIntosh F, Phillips C, Webster R.

J Med Chem. 2007 May 17;50(10):2341-51. Epub 2007 Apr 21.

PMID:
17447747
34.

Assessing detection methods for gel-based proteomic analyses.

Harris LR, Churchward MA, Butt RH, Coorssen JR.

J Proteome Res. 2007 Apr;6(4):1418-25. Epub 2007 Mar 17.

PMID:
17367184
35.

An initial proteomic analysis of human preterm labor: placental membranes.

Butt RH, Lee MW, Pirshahid SA, Backlund PS, Wood S, Coorssen JR.

J Proteome Res. 2006 Nov;5(11):3161-72.

PMID:
17081068
36.

Inhibition of procollagen C-proteinase reduces scar hypertrophy in a rabbit model of cutaneous scarring.

Reid RR, Mogford JE, Butt R, deGiorgio-Miller A, Mustoe TA.

Wound Repair Regen. 2006 Mar-Apr;14(2):138-41.

PMID:
16630102
37.
38.

Actin is not an essential component in the mechanism of calcium-triggered vesicle fusion.

Hibbert JE, Butt RH, Coorssen JR.

Int J Biochem Cell Biol. 2006 Mar;38(3):461-71. Epub 2005 Nov 8.

PMID:
16309945
39.
40.

Enhanced detergent extraction for analysis of membrane proteomes by two-dimensional gel electrophoresis.

Churchward MA, Butt RH, Lang JC, Hsu KK, Coorssen JR.

Proteome Sci. 2005 Jun 7;3(1):5.

41.

A comparative study of the structure of human and murine greater omentum.

Wilkosz S, Ireland G, Khwaja N, Walker M, Butt R, de Giorgio-Miller A, Herrick SE.

Anat Embryol (Berl). 2005 Feb;209(3):251-61. Epub 2005 Jan 21.

PMID:
15662530
42.

Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis.

Hull ML, Prentice A, Wang DY, Butt RP, Phillips SC, Smith SK, Charnock-Jones DS.

Hum Reprod. 2005 Feb;20(2):350-8. Epub 2004 Nov 26.

PMID:
15567877
43.

Increased skin collagen extractability and proportions of collagen type III are not normalized after 6 months healing of human excisional wounds.

Robins SP, Milne G, Duncan A, Davies C, Butt R, Greiling D, James IT.

J Invest Dermatol. 2003 Aug;121(2):267-72.

44.
45.

Unexpected inhibition of fusion in nucleus-nucleus collisions.

Berriman AC, Hinde DJ, Dasgupta M, Morton CR, Butt RD, Newton JO.

Nature. 2001 Sep 13;413(6852):144-7.

PMID:
11557975
46.

How soon is too soon? Addiction recovery and family reunification.

Hohman MM, Butt RL.

Child Welfare. 2001 Jan-Feb;80(1):53-67.

PMID:
11197062
47.

ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada.

Parker AB, Azevedo ER, Baird MG, Smith SJ, Arnold JM, Humen DP, Moe GW, Parker JO, Butt RW, Parker JD.

Am Heart J. 1999 Nov;138(5 Pt 1):843-8.

PMID:
10539814
48.

Mechanical load enhances the stimulatory effect of PDGF on pulmonary artery fibroblast procollagen synthesis.

Bishop JE, Butt R, Dawes K, Laurent G.

Chest. 1998 Jul;114(1 Suppl):25S. No abstract available.

PMID:
9676609
49.
50.

Vascular innervation in atherogenesis.

Butt RD, Scott TM.

Artery. 1997;22(6):336-45.

PMID:
9921408

Supplemental Content

Support Center